ABSTRACT: Natural antigen processing and presentation of antigen is thought to be important for the generation of a broad functional repertoire of antigen-specific T cells. In this study, the T-cell repertoire to an immunodominant human leukocyte antigen A2 (HLA-A2) binding peptide epitope of HER-2/neu, p369-377, was examined in a patient following immunization with a peptidebased vaccine consisting of helper peptides encompassing HLA-A2 peptide epitopes. The responding T-cell repertoire generated was both phenotypically and functionally diverse. A total of 21 p369-377 clones were generated from this patient. With the exception of two clones, all clones were CD3 ϩ . Sixteen of the clones were CD8 ϩ / CD4 Ϫ
INTRODUCTION
One of the most common vaccination strategies used to generate T cells specific for tumor antigen is to use peptides formulated to bind directly to human leukocyte antigen (HLA) molecules eliminating the need for intracellular processing and presentation of antigen. Vaccination with peptides is advantageous compared with other methods, such as using DNA or proteins, for several reasons including the fact that peptides are easily constructed and can be chosen to target specific T-cell subsets, such as cytolytic T cells (CTL) [1] [2] [3] . Vaccination using HLA class I binding peptides have been tested most often because of the availability of HLA class I sequence information and the observations that CTL are critical for antitumor immunity.
Some clinical studies using vaccination with HLA class I binding peptides have reported that peptidespecific precursor frequencies can become elevated, but that these peptide-specific T cells may not recognize naturally processed antigen [4] . The lack of recognition of antigen presented in the major histocompatibility complex (MHC) may be due to the fact that the peptides, usually constructed from motif-based algorithms, were not naturally processed. Alternatively, the high pharmacologic levels of peptides usually administered in a vac-cine could have elicited a T-cell repertoire that cannot respond to the low levels of peptides presented naturally. Thus, it is becoming apparent that natural levels of presentation of peptide antigen, delivered through antigen processing pathways, may be better suited to generate an immune response when using peptide-based vaccines. The levels of endogenously processed antigen presented by antigen presenting cells is a function of many factors including the antigen load as well as the types and amounts of proteasomes present [5] . Several strategies have been developed to deliver peptides to the inside of the cell where natural presentation can be achieved, including mini-gene epitope delivery [6] or fusing the epitopes with molecules designed to deliver the peptides to the endosomal pathway, such as lysosomal membrane associated protein [7] . Another strategy is to deliver the HLA class I peptides that are fully contained within longer helper epitopes, which can result in natural presentation of the encompassed class I peptides [8] .
In this study, we examined the phenotypic and functional diversity of the T-cell repertoire to HER-2/neu peptide p369-377 in a HLA-A2 patient with a HER-2/ neu-overexpressing ovarian cancer. The patient had been previously immunized with a HER-2/neu helper peptide vaccine, which contained the helper peptide p369-386 [8] . This helper peptide encompassed the HLA-A2 peptide, p369-377. Therefore, the resulting p369-377-specific T-cell repertoire produced in vivo was a function of natural processing of antigen.
MATERIALS AND METHODS Patient
The patient was enrolled in a Phase I HER-2/neu peptide-based vaccine trial approved by the University of Washington's Human Subjects Division and the United States Food and Drug Administration, and had received definitive conventional therapy for her disease [8] . This Phase I clinical trial was designed to evaluate safety and immunologic responses to the vaccine. Furthermore, all of the patients had either no evidence of disease or minimal residual stable disease. Clinical responses to vaccine were not possible unless patients were followed for an extended time to relapse. The patient signed a protocol-specific consent and received monthly vaccinations with three 15 amino acid (15-aa) HER-2/neuderived peptides (p369-386, p688-703 and p971-984) containing within each the putative HLA-A2 binding motifs p369-377 [9] , p689-697 [10] , and p971-979 [11] . The vaccine preparation was prepared and delivered as previously described [8] . The patient underwent peripheral blood draws prior to and 30 days following each vaccination for immunologic monitoring. Leukapheresis was obtained 30 days following the final vaccination for the generation of T-cell clones.
Materials
The following peptides used in this study, either for immunization or in vitro use, were as follows: HER-2/neu peptides, p369-386, KIFGSLAFLPESFDGDPA [12] , p688-703, RRLLQETELVEPLTPS [12] , p971-984, ELVSEFSRMARDPQ [12] , and streptavidin-alkaline phosphatase and AP-colorimetric reagents were from BioRad (Hercules, CA, USA). Purified anti-IFN-␥ (clone # 1-D1K) and biotin-conjugated anti-IFN-␥ (clone # 7-B6-1) were purchased from Mabtech AB (Nacka, Sweden). Anti-CD8-FITC, anti-CD4-PE, anti-␥␦-TCR, and anti-␣␤-TCR antibodies were purchased from Pharmingen (San Diego, CA, USA). HLA testing was performed by the Puget Sound Blood Bank (Seattle, WA, USA).
Cell Lines
Epstein-Barr virus (EBV) transformed B-lymphoblastoid cell lines (BLCL) were produced from peripheral blood mononuclear cells (PBMC) using culture supernatant from the EBV-producing B95-8 cell line (American Type Culture Collection, Manassas, VA, USA). The HER-2/neu-overexpressing cell lines SKOV3 and SKOV3-A2, and BLCLs were maintained in RPMI-1640 with L-glutamine, penicillin, streptomycin, 2-mercaptoethanol, and 10% fetal calf serum. The SKOV3-A2 tumor cells are the same as SKOV3 tumor cells, except that they are stably transfected with a vector encoding HLA-A2 [13] .
Preparation of PBMC and Cloning of Peptide-Specific T Cells PBMC were isolated by density gradient centrifugation as previously described [12] . Cells were analyzed immediately or aliquoted and cryopreserved in liquid nitrogen in freezing media (90% fetal bovine serum and 10% dimethylsulfoxide) at a cell density of 25 to 50ϫ10 6 cells/ml until use. Antigen-specific T-cell clones were generated by culturing 25ϫ10 6 PBMC in T25 tissue culture flasks in 20 ml of T-cell medium. The HLA-A2 peptide, p369-377, was added to the flasks to 1 M. The flasks were incubated at 37°C and 5% CO 2 . On day 3 and every other subsequent day, IL-2 was added to 5 U/ml. On day 10, in vitro stimulation was performed with peptide-pulsed, irradiated autologous PBMC. The cultures were further incubated for an additional 10 days with periodic IL-2 administration. T-cell clones were derived from the T-cell lines after two in vitro stimulations. For cloning, bulk cultures were diluted to achieve approximately 0.3 viable cells/200 l and plated onto four flat-bottom 96-well plates in complete medium. Peptide-pulsed, irradiated autologous PBMC (2.0ϫ10 5 ) were added to each well in the presence of 50 U/ml IL-2. The wells were then tested for lytic activity in a 51 Cr release assay using 50 l of cells from each well after 14 days. Positive wells were identified as those having specific activity of 5% or greater. The positive wells were transferred to new 96-well plates and subsequently restimulated with peptide-pulsed, irradiated autologous BLCL.
The cultures were eventually expanded and carried using IL-2 and peptide-pulsed, irradiated autologous BLCL.
T-Cell Proliferation Assays
HER-2/neu-specific T-cell proliferative responses were measured at baseline and at the end of the study. T-cell proliferation was assessed using a modified limiting dilution assay designed for detecting low frequency lymphocyte precursors based on Poisson distribution as previously described [12, 14] . HER-2/neu peptide-specific T-cell responses were measured at baseline and at the time of the final vaccination using freshly prepared PBMC. PBMC were prepared by Ficoll-Paque (Pharmacia AB, Uppsala, Sweden) centrifugation and resuspended in media consisting of equal parts of EHAA 120 (Biofluids, Inc.) and RPMI 1640 (Gibco, Grand Island, NY, USA) with L-glutamine, penicillin/streptomycin, ␤-2 ME, and 10% AB serum (ICN Flow, Costa Mesa, CA). PBMC were cocultured with 50 g/ml of the various individual HER-2/neu peptides. Specifically, 2ϫ10 5 PBMC/well were plated into 96-well round bottom microtiter plates (Costar, Cambridge, MA, USA) with antigen at 37°C in an atmosphere of 5% CO 2 for 5 days. All antigens were tested in 24-well replicates. Eight hours before termination of culture, each well was pulsed with 1 Ci 3 H-thymidine (New England Nuclear, Wilmington, DE). The cultures were then harvested onto glass fiber filters and the incorporated radioactivity was measured with a Microbeta 1450 scintillation counter (Wallac). Peripheral blood T-cell response data presented here is expressed as a standard stimulation index (SI), which is defined as the mean of all 24 experimental wells divided by the mean of the 24 control wells (no antigen). An age-matched control population of 30 volunteer blood donors was analyzed similarly (data not shown). No volunteer donor had a response to HER-2/neu peptides. The mean and 3 standard deviations of the volunteer donor responses to all antigens (SI of 1.98) established a baseline, therefore an SI of Ͼ 2 was considered consistent with an immunized response.
Enzyme-Linked Immunosorbant Spot
An enzyme-linked immunosorbent spot (ELIspot) assay was used to determine precursor frequencies of peptidespecific T lymphocytes as previously described with some minor modifications [8] . On day 1, 2.5ϫ10 4 viable cells, as determined by trypan blue staining were plated, in quadruplicate, into 96-well, anti-IFN-␥-coated nitrocellulose plates in 100 l media. Because at 10 days following restimulation some irradiated PBMC and BLCL can still exclude trypan blue, the viable cell counts do not reflect the true numbers of each antigen-specific clonal population. Thus, our ELIspot analysis is only able to measure the numbers of cells responding to antigen and not the proportion of the antigen-specific T-cell clones that are responding with IFN-␥ release. The cells were stimulated with 100 l of media containing 2.0ϫ10 5 autologous, irradiated (3000 rads) BLCLs prepulsed (1 h, RT) with or without antigen (10 g/ml). The cells were further incubated for 20 h at 37°C and detection of bound IFN-␥ was performed as previously described [8] . Cr]-release assays as previously described [8] . The percent specific activity was calculated using the following equation: % specific lysis ϭ (sample well release Ϫ basal release)/(detergent release Ϫ basal release).
Flow Cytometry
Clones were harvested and washed in FACS staining buffer (PBS containing 20-mM glucose and 0.5% BSA). Cells were stained in 50-l FACS staining buffer containing control antibody, anti-CD4, anti-CD8, anti-␣␤-TCR, anti-␥␦-TCR, or anti-CD3, for 1-2 h at 4°C. Following two washes the cells were fixed in PBS containing 1% paraformaldehyde and analyzed by flow cytometry. Data presentation was completed using CellQuest flow cytometry software (Becton-Dickinson Immunocytometry Systems, San Jose, CA, USA).
RESULTS
Immunity to HER-2/neu peptide p369-386 is generated as a result of vaccination with helper peptides in an HLA-A2 ϩ ovarian cancer patient. T-cell proliferative responses were measured against 15-aa HER-2/neu peptides prior to, during, and following the vaccination series. As illustrated in Figure 1A , prior to immunization proliferative responses were not detected to any of the HER-2/neu peptides contained within the vaccine formulation. The stimulation index to p369-386 was 0.9, to p688-p703 was 0.9, and to p971-984 was 0.8. The patient demonstrated a proliferative response to tetanus toxoid (SI ϭ 7.5). Following vaccination, 6 months after the initial immunization, a T-cell proliferative response was measured against 15-aa HER-2/neu peptide, p369-386 ( Figure 1B) . The stimulation index to p369-386 was 4.2, to p688-p703 was 1.4, and to p971-984 was 1.6. The tetanus toxoid response remained stable during the course of immunization and after the last vaccine was 4.9. The peptide, p369-386, encompassed within its sequence a defined HLA-A2 binding epitope, p369-377 [8, 15] . Twenty-one T-cell clones were isolated using this HLA-A2 peptide, representing a cloning efficiency of approximately 5%.
A polyclonal T-cell response could be elicited to p369-377, an HLA-A2 HER-2/neu epitope encompassed with the sequence of the helper epitope, after active immunization. The majority (19/21) of the clones were Ͼ 90% CD3 Figure 3 . Representative clones from each phenotypic group both ␣␤ or ␥␦ were chosen for evaluation in a more detailed fashion.
HER-2/neu peptide-specific ␣␤-TCR clones secrete IFN-␥ in response to antigen. The ␣␤-TCR clones were examined for peptide-specific release of IFN-␥ in an ELIspot assay (Figure 4) . Representative ␣␤-TCR, CD8ϩ T cells were tested against p369-377, an irrelevant HER-2/neu 9 amino acid peptide, or no antigen. The number of spots detected in wells containing p369-377 was 137 Ϯ 17 (mean Ϯ standard error of mean [SEM]), 177 Ϯ 22, and 102 Ϯ 17, for the clones, 3H8 (CD8), 2G2 (CD8), and 2F6 (CD8) respectively. These means were significantly greater than the mean number 
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ϩ (3G9) are revealed in Figure 5 . The clones examined all demonstrated detectable lysis of p369-377-loaded BLCL and HLA-A2 ϩ HER-2/neu-expressing tumor cells. At an effector:target (E:T) ratio of 40:1, the percent of specific lysis was 9%, 12%, and 13% for clones 2G2 (Panel A), 2G7 (Panel B), and 3G9 (Panel C), respectively against p369-377-loaded autologous BLCL. Responses against non peptide-loaded BLCL were Ͻ 4% for all clones tested. Against the HLA-A2ϩ, HER-2/neu-expressing SKOV3 tumor cell line, the percent of specific lysis at 40:1 E:T was 7%, 7%, and 6% for 2G2 (Panel A), 2G7 (Panel B), and 3G9 (Panel C), respectively. Lysis of parental, HER-2-expressing SKOV3 tumor cells was not detectable for any of the tested clones.
The ␥␦-TCR clones secrete IFN-␥ and lyse HLA-A2 ϩ , HER-2/neu-expressing tumor cells. The ␥␦-TCR clones were examined for expression of CD4, CD8 (Figure 6 ). Clone 3F7 was predominantly CD8 ϩ . In contrast, clone 1D1 displayed heterogeneous but consistent expression of CD4 and CD8. As assessed by flow cytometry expression of the ␥␦-TCR was observed in 90% of cells (Figure 2) . The remaining 10% expressed neither CD3 (not shown) nor ␥␦-TCR suggesting nonspecific particulate debris. Approximately 50% of 1D1 expressed CD8, 10% expressed CD4, and the remaining 40% did not express either CD8 or CD4 (Figure 6 ). Peptide-specific release of IFN-␥ against p369-377, an irrelevant HLA-A2 HER-2/neu peptide p1066-1074, or no antigen was examined in an ELIspot assay (Figure 7) . The mean number of spots detected in wells containing p369-377 was 57 (Ϯ 7, SEM) and 6 (Ϯ 1, SEM) for 1D1 and 3F7 respectively. The mean number of spots, in the presence of p369-377, for 1D1 was significantly higher than the mean number of spots detected in wells containing either no antigen (19 Ϯ 4, SEM, p ϭ 0.015) or irrelevant peptide (26 Ϯ 8, SEM, p ϭ 0.03). Clone 3F7 did not demonstrate significantly elevated IFN-␥ release in response to peptide.
The ␥␦-TCR clones were also examined for lysis of HER-2/neu-expressing cells lines (Figure 8 ). Both clones displayed lysis of the HLA-A2 ϩ , HER-2/neu-expressing tumor cell line SKOV3-A2. At an E:T ratio of 40:1, the percent of specific lysis was 25% and 20% for 1D1 (Panel A) and 3F7 (Panel B), respectively. Lysis of parental HER-2-expressing SKOV3 tumor cells was Ͻ 1% for both clones at all E:T ratios examined.
CONCLUSIONS
We immunized patients with T-helper epitopes derived from HER-2/neu, each of which encompassed known HLA class I motifs to generate HER-2/neu-specific CTL in cancer patients [8] . Clinical vaccination with longer peptides encompassing HLA class I binding motifs allowed exogenous uptake of helper epitopes within the HLA class II processing pathway. Once internalized and processed, peptides are available to the HLA-class I processing pathway for presentation [16] . Thus, the subsequent stimulation of HLA class I restricted T cells represents an immune response that likely required internal processing and presentation of antigen rather than exogenous peptide loading. We cloned T cells from a patient successfully immunized with a T-helper peptide (p369-386) derived from HER-2/neu to evaluate the repertoire of the HLA class I specific peptide (p369-377) encompassed within the longer epitope. The studies described here demonstrate substantial diversity of the vaccinated repertoire, which consisted not only of CD4 ϩ and CD8 T cells, but also ␣␤-TCR and ␥␦-TCR T cells specific for HLA class I, HER-2/neu peptide antigen. As expected, the majority of peptide-specific clones isolated were CD8 ϩ ; however, nearly 25% of the clones identified were CD4 ϩ . A representative clone of the CD4 ϩ T-cell population could lyse both peptide-loaded BLCL as well as HER-2/neu overexpressing HLA-A2 tumor cells. The lysis observed by CD4 ϩ T-cell clones was weak and of similar magnitude to the lysis observed by the CD8 ϩ T-cell clones, a finding that is consistent with previous studies of HER-2/neu-specific T-cell lines or clones [4, 10, 15, 17] . Isolation of T cells with weak lytic activity is likely due to loss of higher affinity T cells against self antigens by tolerizing mechanisms [18] . HLA class II restricted cytolytic CD4 ϩ T cells have been defined and have been described to play a roles in the pathogenesis of autoimmune disease via responses to self antigens, such as myelin [19] . Reports of HLA class I restricted CD4ϩ T cells are rare. There have been only a few reports of cytolytic CD4 ϩ T cells responding to HLA class I peptides in melanoma [17, 20] . One study was a report of a HLA-B57-restricted CD4 ϩ cytolytic clone, which could lyse autologous melanoma and allogeneic 
FIGURE 6
The ␥␦ T-cell receptor (␥␦-TCR) T-cell clones could be isolated following HER-2/neu vaccination. This illustrates the flow cytometry data of p369-377-specific ␥␦-TCR T-cell clones dual-stained for both CD4 and CD8 (top row). Background irrelevant staining (FITC-conjugated antimouse IgG) for the same clones are depicted in the bottom row. The results are representative of two independent experiments yielding similar results. melanoma lines that were matched for HLA-B57 [16] . Nishimura and colleagues [17] performed a more extensive analysis of a CD4 ϩ T-cell line derived from tumor infiltrating lymphocytes derived from a melanoma patient. The CD4 ϩ T cells were specific for a tyrosinase peptide, p368-376, secreted cytokines of a Th1 phenotype and were weakly cytolytic. Furthermore, although the cell line demonstrated high CD4 expression, CD4 apparently was not involved in antigen-specific signaling through the TCR. The authors concluded that the HLA class I restricted CD4 ϩ T cell was most likely a rare event with unknown functional significance. Data presented here suggests the HLA class I restricted CD4 ϩ T cells may be present in number greater than previously thought. Whether the functional importance of these cells lay in direct killing or regulating the immune response through cytokine secretion is currently unknown.
Most analyses of the T-cell repertoire generated in response to dominant HLA class I epitopes have focused exclusively ␣␤-TCR ϩ , CD3 ϩ , CD8
ϩ T cells. Specifically, investigations have analyzed the V␤ usage and the CDR3 size of the ␣␤-TCR of viral peptide-specific T cells [21, 22] . In general, findings from viral studies suggest that the repertoire to dominant viral epitopes is tightly restricted in terms of TCR usage. Recently, however, Dietrich and colleagues [23] examined the clonality of the T-cell repertoire to an HLA-A2 restricted immunodominant epitope of the melanoma-associated antigen, Melan-A. They observed, by analyzing the V␤ segment and CDR3 lengths, that the natural repertoire to this self peptide was considerably broader than what had been previously observed in viral peptide systems, suggesting that the ␣␤-TCR usage is not as narrowly restricted in response to tumors as it is in viral infections. As expected, in the present study, the predominant TCR was the ␣␤-TCR. However, 2 of 21 clones (10%) expressed ␥␦-TCR. ␥␦-TCR T cells are involved in a wide range of immune responses to infectious and non-infectious diseases, including malaria, mycobacterial infections, cancers, and autoimmune disorders, such as multiple sclerosis [24] . The ␥␦-TCR T-cell clones have been isolated from tumor-infiltrating lymphocytes derived from tumors, such as dysgerminoma [25] , seminoma [25] , renal carcinoma [26] , lung [27] , colorectal [28] , and melanoma [29] . Tumor-associated ␥␦-TCR T cells that have been described in colorectal cancers have a CD8 ϩ , cytolytic phenotype similar to those described in the present study [27] . In the present study, ␥␦-TCR T-cell clone 1D1, displayed heterogeneous expression of CD4 or CD8. In general, circulating ␥␦-TCR T cells do not express CD4 or CD8, which is distinct from ␣␤-TCR T cells in which either CD4 or CD8 expression occurs during early thymocyte ontogeny [30] . Little is known about the regulation of expression of CD4 and CD8 in ␥␦-TCR T cells, but since the majority of circulating ␥␦-TCR T cells are CD4 Ϫ /CD8 Ϫ , it is thought that some coreceptor upregulation may be due to environmental maturation [24, 31] . Therefore, it is possible that the differential expression of CD8 and CD4 in our clonal population was induced by in vitro maturation that could have led to clonal divergence [32] .
In autoimmune diseases, pathology has been attributed to infiltrating ␥␦-TCR T cells. For example, antibody depletion of ␥␦-TCR reduces demyelination and inflammation in experimental murine multiple sclerosis [33] . It is unknown if autoreactive ␥␦-TCR T cells respond secondarily to damaged and stressed tissue [34] or if they initiate autoimmunity directly. One hypothesis [35] is that, given the broad range of regulation by multiple mechanisms of antigen presentation and natural localization to epithelial tissue, ␥␦-TCR T cells are sentinels for the immune system and are capable of alerting the immune system to the presence of danger (e.g., infection, tumors, etc.).
Immunization against tumor antigens in cancer patients with peptide-based vaccines has been best studied in patients with existing disease burden and clinical responses have occurred only infrequently [36, 37] . We hypothesize that vaccines may be better suited for the prevention of relapse following conventional therapies [8] . Nevertheless, characterization of the T-cell response to tumor antigen-specific peptide vaccines is necessary for optimizing design and improving clinical outcome.
The results presented here demonstrate that the T-cell population specific for the HER-2/neu peptide, p369-377 elicited after active immunization is polyclonal both at the level of the TCR and the T-cell subsets stimulated. These data reflect the distinct differences between the highly monoclonal immunodominant responses directed against foreign infectious disease antigens and the diverse polyclonal response against self tumor antigens. Many of the elements in the immune response described in this report are important in the autoimmunity (i.e., CD4 ϩ cytolytic T cells and ␥␦TCR T cells). Perhaps functional immunity directed against specific self antigens mimics the pathogenic pathways of autoimmune disease closer than anticipated.
